^
Association details:
Biomarker:EGFRvIII mutation
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

Excerpt:
Additionally, we found that the EGFRvIII mutant, which does not have a mutation in the kinase domain, was also more sensitive to gefitinib than wild type EGFR in transfected cells (Figures 1 and 2). 
DOI:
10.1038/sj.onc.1209159